Of note, diflunisal was the first TTR stabilizer to demonstrate clinical benefit in ATTRv polyneuropathy37 and cardiomyopathy,38, 39, 40 but it is not approved by Health Canada for any ATTRv indication. The gene discussed is TTR; the disease is cardiomyopathy.